Literature DB >> 6735039

[Systemic circulatory hyperkinetic syndrome in patients with cirrhosis. Relation with hepatocellular failure and portal hypertension].

D Valla, T Poynard, E Bercoff, C Bataille, G Goldfarb, D Lebrec.   

Abstract

Hyperkinetic circulatory state is common in patients with cirrhosis but the cause of this syndrome has not been clearly elucidated. Systemic hemodynamic changes and their relationship to liver failure and splanchnic hemodynamics were studied in 100 patients with cirrhosis and were compared to a group of 15 patients without portal hypertension. Cardiac output was significantly higher and systemic vascular resistance was significantly lower in cirrhotic patients than in control patients. Multivariate analysis revealed that among different clinical, biochemical and splanchnic hemodynamic data, serum albumin, serum bilirubin, plasma prothrombin, and gastrointestinal bleeding significantly and independently explained the variation of cardiac output and systemic vascular resistance. No relationship was found between hepatic venous pressures or the presence of ascites and the hyperkinetic syndrome. From these results, it is concluded that in patients with cirrhosis liver failure is partly responsible for the hyperkinetic state.

Entities:  

Mesh:

Year:  1984        PMID: 6735039

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  3 in total

1.  Influence of the degree of liver failure on systemic and splanchnic haemodynamics and on response to propranolol in patients with cirrhosis.

Authors:  A Braillon; P Cales; D Valla; D Gaudy; P Geoffroy; D Lebrec
Journal:  Gut       Date:  1986-10       Impact factor: 23.059

Review 2.  Cardiac abnormalities in liver cirrhosis.

Authors:  S S Lee
Journal:  West J Med       Date:  1989-11

3.  Alterations in isoprenaline sensitivity in patients with cirrhosis: evidence of abnormality of the sympathetic nervous activity.

Authors:  M J Ramond; E Comoy; D Lebrec
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.